480 related articles for article (PubMed ID: 27243590)
1. Validation of a Simple 0 to 10 Numerical Score (IBD-10) of Patient-reported Inflammatory Bowel Disease Activity for Routine Clinical Use.
Subramanian S; Asher R; Weston W; Rimmer M; McConville A; Malin A; Jackson R; Collins P; Probert C; Dibb M; Rhodes JM
Inflamm Bowel Dis; 2016 Aug; 22(8):1902-7. PubMed ID: 27243590
[TBL] [Abstract][Full Text] [Related]
2. Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease.
Zittan E; Kelly OB; Kirsch R; Milgrom R; Burns J; Nguyen GC; Croitoru K; Van Assche G; Silverberg MS; Steinhart AH
Inflamm Bowel Dis; 2016 Mar; 22(3):623-30. PubMed ID: 26829408
[TBL] [Abstract][Full Text] [Related]
3. Disease activity assessment in IBD: clinical indices and biomarkers fail to predict endoscopic remission.
Falvey JD; Hoskin T; Meijer B; Ashcroft A; Walmsley R; Day AS; Gearry RB
Inflamm Bowel Dis; 2015 Apr; 21(4):824-31. PubMed ID: 25738372
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China.
Chen JM; Liu T; Gao S; Tong XD; Deng FH; Nie B
World J Gastroenterol; 2017 Dec; 23(46):8235-8247. PubMed ID: 29290660
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers.
Ricanek P; Brackmann S; Perminow G; Lyckander LG; Sponheim J; Holme O; Høie O; Rydning A; Vatn MH;
Scand J Gastroenterol; 2011 Sep; 46(9):1081-91. PubMed ID: 21619483
[TBL] [Abstract][Full Text] [Related]
6. Bi-directionality of Brain-Gut Interactions in Patients With Inflammatory Bowel Disease.
Gracie DJ; Guthrie EA; Hamlin PJ; Ford AC
Gastroenterology; 2018 May; 154(6):1635-1646.e3. PubMed ID: 29366841
[TBL] [Abstract][Full Text] [Related]
7. High Percentage of IBD Patients with Indefinite Fecal Calprotectin Levels: Additional Value of a Combination Score.
Bodelier AG; Jonkers D; van den Heuvel T; de Boer E; Hameeteman W; Masclee AA; Pierik MJ
Dig Dis Sci; 2017 Feb; 62(2):465-472. PubMed ID: 27933473
[TBL] [Abstract][Full Text] [Related]
8. Relationship of clinical symptoms with biomarkers of inflammation in pediatric inflammatory bowel disease.
Hoekman DR; Diederen K; Koot BG; Tabbers MM; Kindermann A; Benninga MA
Eur J Pediatr; 2016 Oct; 175(10):1335-42. PubMed ID: 27573259
[TBL] [Abstract][Full Text] [Related]
9. Granulocytapheresis in steroid-dependent and steroid-resistant patients with inflammatory bowel disease: a prospective observational study.
Sacco R; Romano A; Mazzoni A; Bertini M; Federici G; Metrangolo S; Parisi G; Nencini C; Giampietro C; Bertoni M; Tumino E; Scatena F; Bresci G
J Crohns Colitis; 2013 Dec; 7(12):e692-7. PubMed ID: 23870727
[TBL] [Abstract][Full Text] [Related]
10. Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG).
Eriksson C; Marsal J; Bergemalm D; Vigren L; Björk J; Eberhardson M; Karling P; Söderman C; ; Myrelid P; Cao Y; Sjöberg D; Thörn M; Karlén P; Hertervig E; Strid H; Ludvigsson JF; Almer S; Halfvarson J
Scand J Gastroenterol; 2017; 52(6-7):722-729. PubMed ID: 28362144
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort.
Shelton E; Allegretti JR; Stevens B; Lucci M; Khalili H; Nguyen DD; Sauk J; Giallourakis C; Garber J; Hamilton MJ; Tomczak M; Makrauer F; Burakoff RB; Levine J; de Silva P; Friedman S; Ananthakrishnan A; Korzenik JR; Yajnik V
Inflamm Bowel Dis; 2015 Dec; 21(12):2879-85. PubMed ID: 26288002
[TBL] [Abstract][Full Text] [Related]
12. CD4+ immune response as a potential biomarker of patient reported inflammatory bowel disease (IBD) activity.
Brandhorst G; Weigand S; Eberle C; Raddatz D; Karaus M; Oellerich M; Walson PD
Clin Chim Acta; 2013 Jun; 421():31-3. PubMed ID: 23485644
[TBL] [Abstract][Full Text] [Related]
13. Comparison of fecal calprotectin and serum C-reactive protein in early prediction of outcome to infliximab induction therapy.
Engström J; Lönnkvist M; Befrits R; Ljung T; Diaz-Tartera H; Holst M; Hellström PM
Scand J Gastroenterol; 2019 Sep; 54(9):1081-1088. PubMed ID: 31499013
[No Abstract] [Full Text] [Related]
14. Pancreatitis-associated protein has no additional value as a marker of disease activity in a real-life cohort of IBD patients.
Bodelier AG; Pierik MJ; van den Heuvel T; Bovee-Oudenhoven IM; de Boer E; Hameeteman W; Masclee AA; Jonkers D
Eur J Gastroenterol Hepatol; 2014 Aug; 26(8):902-9. PubMed ID: 24915490
[TBL] [Abstract][Full Text] [Related]
15. TWEAK is not elevated in patients with newly diagnosed inflammatory bowel disease.
Grimstad T; Skoie IM; Doerner J; Isaksen K; Karlsen L; Aabakken L; Omdal R; Putterman C
Scand J Gastroenterol; 2017 Apr; 52(4):420-424. PubMed ID: 28040992
[TBL] [Abstract][Full Text] [Related]
16. The use of serum calprotectin as a biomarker for inflammatory activity in inflammatory bowel disease.
Suárez Ferrer C; Abadía Barno M; Martín Arranz E; Jochems A; García Ramírez L; Poza Cordón J; Jaquotot Herranz M; Cerpa Arencibia A; Martín Arranz MD
Rev Esp Enferm Dig; 2019 Oct; 111(10):744-749. PubMed ID: 31476872
[TBL] [Abstract][Full Text] [Related]
17. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
[TBL] [Abstract][Full Text] [Related]
18. Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study.
Smits LJ; Derikx LA; de Jong DJ; Boshuizen RS; van Esch AA; Drenth JP; Hoentjen F
J Crohns Colitis; 2016 Nov; 10(11):1287-1293. PubMed ID: 27095751
[TBL] [Abstract][Full Text] [Related]
19. Vedolizumab is effective and safe in real-life treatment of inflammatory bowel diseases outpatients: A multicenter, observational study in primary inflammatory bowel disease centers.
Tursi A; Mocci G; Faggiani R; Allegretta L; Valle ND; Medici A; Forti G; Franceschi M; Ferronato A; Gallina S; Grasso G; Larussa T; Luzza F; Lorenzetti R; Penna A; Rodino' S; Sebkova L; Lauria A; Piergallini S; Pranzo G; Scorza S; Zampaletta C; Picchio M; Elisei W
Eur J Intern Med; 2019 Aug; 66():85-91. PubMed ID: 31208827
[TBL] [Abstract][Full Text] [Related]
20. Impaired Intestinal Permeability Contributes to Ongoing Bowel Symptoms in Patients With Inflammatory Bowel Disease and Mucosal Healing.
Chang J; Leong RW; Wasinger VC; Ip M; Yang M; Phan TG
Gastroenterology; 2017 Sep; 153(3):723-731.e1. PubMed ID: 28601482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
